Tuberc Respir Dis.  2006 Aug;61(2):114-120.

Respiratory Review of 2006: Asthma

• Lee KY
• Lee YC

Abstract

No abstract available.

MeSH Terms

Asthma*

Reference

1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000. 162:2341–2351.

2. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994. 10:471–480.

3. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992. 89:958–967.

4. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995. 152:76–80.

5. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med. 2006. 354:697–708.

6. Ohkawara Y, Yamauchi K, Tanno Y, Tamura G, Ohtani H, Nagura H, et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol. 1992. 7:385–392.

7. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumor necrosis factor (TNF-α) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005. 60:1012–1018.

8. Erzurum SC. Inhibition of tumor necrosis factor α for refractory asthma. N Engl J Med. 2006. 354:754–758.

9. Choi IW, Kim YS, Kim DK, Choi JH, Seo KH, Im SY, et al. Platelet-activating factor-mediated NF-κB dependency of a late anaphylactic reaction. J Exp Med. 2003. 198:145–151.

10. Choi IW, Kim S, Kim YS, Ko HM, Im SY, Kim JH, et al. TNF-α induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phsopholipase A(2) activation. J Allergy Clin Immunol. 2005. 116:537–543.

11. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic disease. J Allergy Clin Immunol. 2005. 116:961–968.

12. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006. 116:146–155.

13. Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol. 2002. 109:369–370.

14. John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med. 1998. 157:256–262.

15. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. Physiology. 2005. 20:28–35.

16. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeablity, and angiogenesis. Am J Pathol. 1995. 146:1029–1039.

17. Lee YC, Lee HK. Vascular endothelial growth factor in patients with acute asthma. J Allergy Clin Immunol. 2001. 107:1106.

18. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol. 2001. 107:1034–1038.

19. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001. 107:295–301.

20. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Immunol. 2002. 168:3595–3600.

21. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances Th2-meidated sensitization and inflammation in the lung. Nat Med. 2004. 10:1095–1103.

22. Chetta A, Zanini A, Foresi A, D'Ippolito R, Tipa A, Castagnaro A, et al. Vascular endothelial growth factor up-regulation and bronchial wall remodeling in asthma. Clin Exp Allergy. 2005. 35:1437–1442.

23. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interluekin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med. 2001. 194:809–821.

24. Karagiannidis C, Hense G, Martin C, Epstein M, Ruckert B, Mantel PY, et al. Activin A is an acute allergen-responsive cytokine and provides a link to TGF-β-mediated airway remodeling in asthma. J Allergy Clin Immunol. 2006. 117:111–118.

25. Ezeamuzie CI, Sukumaran J, Philips E. Effect of wortmannin on humna esoinophil responses in vitro and on bronchial inflammation and airwa hyperresponsiveness inGuinea pigs in vivo. Am J Respir Crit Care Med. 2001. 164:1633–1639.

26. Tigani B, Hannon JP, Mazzoni L, Fozard JR. Effects of wortmannin on airways inflammation induced by allergen in actively sensitised Brown Norway rats. Eur J Pharmacol. 2001. 433:217–223.

27. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest. 2003. 111:1083–1092.

28. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002. 53:409–435.

29. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, et al. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J. 2005. 19:1033–1035.

30. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996. 14:649–683.

31. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappa B, in asthma. Am J Respir Crit Care Med. 1998. 158:1585–1592.

32. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-β promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med. 1998. 158:1958–1962.

33. Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med. 1994. 180:711–715.

34. Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, et al. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. Mol Pharmacol. 2005. 68:1568–1575.

35. Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD. Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 2006. 20:455–465.

36. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol. 2005. 116:292–298.

37. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005. 365:167–175.